Japan's Nichi-Iko prepping for US biosimilar entry
This article was originally published in Scrip
Executive Summary
The major Japanese generics firm Nichi-Iko has signalled its intention to move into the biosimilars sector in the US through the establishment of a new subsidiary in this market.